• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by 2seventy bio Inc. (Amendment)

    2/14/24 4:21:54 PM ET
    $TSVT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TSVT alert in real time by email
    SC 13G/A 1 tm242424d4_sc13ga.htm SC 13G/A

     

     

     

    SCHEDULE 13G

     

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    2seventy bio, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    901384107

     

     

    (CUSIP Number)

     

    December 31, 2023

     

     

      (Date of Event which Requires Filing of this Statement)  

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    ¨ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 901384107

     

    1

    NAMES OF REPORTING PERSONS

     

    Baker Bros. Advisors LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨
    (b) 
    ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5

    SOLE VOTING POWER

     

    2,527,672 (1)

    6

    SHARED VOTING POWER

     

    -0-

    7

    SOLE DISPOSITIVE POWER

     

    2,527,672 (1)

    8

    SHARED DISPOSITIVE POWER

     

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,527,672 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)

    ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.99% (1)(2)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IA, PN

    (1)Includes 30,146 shares of Common Stock (“Common Stock”) of 2seventy bio, Inc. (the “Issuer”) issuable upon the exercise of Pre-Funded Warrants (as defined in Item 4 and subject to limitations as described therein) held directly by the Funds (as defined in Item 4).
     (2)Based on 50,624,606 shares of Common Stock outstanding as of November 8, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission (“SEC”) on December 1, 2023, plus 30,146 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (as defined in Item 4) that are subject to limitations on exercise described in Item 4.

     

     

    CUSIP No. 901384107

     

    1

    NAMES OF REPORTING PERSONS

     

    Baker Bros. Advisors (GP) LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨
    (b) 
    ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

      Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5

    SOLE VOTING POWER

     

    2,527,672 (1)

    6

    SHARED VOTING POWER

     

    -0-

    7

    SOLE DISPOSITIVE POWER

     

    2,527,672 (1)

    8

    SHARED DISPOSITIVE POWER

     

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,527,672 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)

    ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.99% (1)(2)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    HC, OO

    (1) Includes 30,146 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants (as defined in Item 4 and subject to limitations as described therein) held directly by the Funds (as defined in Item 4).
    (2) Based on 50,624,606 shares of Common Stock outstanding as of November 8, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on December 1, 2023, plus 30,146 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (as defined in Item 4) that are subject to limitations on exercise described in Item 4.

     

     

    CUSIP No. 901384107

     

    1

    NAMES OF REPORTING PERSONS

     

    Felix J. Baker

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨
    (b) 
    ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5

    SOLE VOTING POWER

     

    2,527,672 (1)

    6

    SHARED VOTING POWER

     

    -0-

    7

    SOLE DISPOSITIVE POWER

     

    2,527,672 (1)

    8

    SHARED DISPOSITIVE POWER

     

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,527,672 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)

    ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.99% (1)(2)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN, HC

    (1)  Includes 30,146 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants (as defined in Item 4 and subject to limitations as described therein) held directly by the Funds (as defined in Item 4).
    (2) Based on 50,624,606 shares of Common Stock outstanding as of November 8, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on December 1, 2023, plus 30,146 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (as defined in Item 4) that are subject to limitations on exercise described in Item 4.

     

     

    CUSIP No. 901384107

     

    1

    NAMES OF REPORTING PERSONS

     

    Julian C. Baker

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)

    (a) ¨
    (b) 
    ¨

     

    3

    SEC USE ONLY

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5

    SOLE VOTING POWER

     

    2,527,672 (1)

    6

    SHARED VOTING POWER

     

    -0-

    7

    SOLE DISPOSITIVE POWER

     

    2,527,672 (1)

    8

    SHARED DISPOSITIVE POWER

     

    -0-

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,527,672 (1)

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (See Instructions)

    ¨

     

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    4.99% (1)(2)

    12

    TYPE OF REPORTING PERSON (See Instructions)

     

    IN, HC

    (1)  Includes 30,146 shares of Common Stock issuable upon the exercise of Pre-Funded Warrants (as defined in Item 4 and subject to limitations as described therein) held directly by the Funds (as defined in Item 4).
    (2) Based on 50,624,606 shares of Common Stock outstanding as of November 8, 2023, as reported in the Issuer’s Form 10-Q filed with the SEC on December 1, 2023, plus 30,146 shares of Common Stock issuable upon exercise of Pre-Funded Warrants (as defined in Item 4) that are subject to limitations on exercise described in Item 4.

     

     

    Amendment No. 1 to Schedule 13G 

     

    This Amendment No. 1 to Schedule 13G amends the previously filed Schedule 13G filed by Baker Bros. Advisors LP (the “Adviser”), Baker Bros. Advisors (GP) LLC (the “Adviser GP”), Julian C. Baker and Felix J. Baker (collectively, the “Reporting Persons”). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain in full force and effect.

     

    Item 1(a) Name of Issuer:

     

    2seventy bio, Inc. (the “Issuer”)

     

    Item 1(b) Address of Issuer’s Principal Executive Offices:

     

    60 Binney Street

     

    Cambridge, MA 02142

     

    Item 2(a) Name of Person Filing:

     

    This Amendment No. 1 is being filed jointly by the Reporting Persons.

     

    Item 2(b) Address of Principal Business Office or, if None, Residence:

     

    The business address of each of the Reporting Persons is:

     

    c/o Baker Bros. Advisors LP

     

    860 Washington Street, 3rd Floor

     

    New York, NY 10014

     

    (212) 339-5690

     

    Item 2(c) Citizenship:

     

    The Adviser is a limited partnership organized under the laws of the State of Delaware. The Adviser GP is a limited liability company organized under the laws of the State of Delaware. The citizenship of each of Julian C. Baker and Felix J. Baker is the United States of America.

     

    Item 2(d) Title of Class of Securities:

     

    Common Stock, par value $0.0001 per share (“Common Stock”).

     

    Item 2(e) CUSIP Number:

     

    901384107

     

     

    Item 3 If this statement is filed pursuant to §§240.13d-1(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under Section 15 of the Exchange Act.

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Exchange Act.

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Exchange Act.

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940.

     

    (e) x An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).

     

    (f)  ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.

     

    (i)  ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940.

     

    (j)  ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

     

    Item 4 Ownership:

     

    Items 5 through 9 and 11 of each of the cover pages to this Amendment No. 1 are incorporated herein by reference. Set forth below is the aggregate number of shares of Common Stock directly held by each of Baker Brothers Life Sciences, L.P. (“Life Sciences”) and 667, L.P. (“667”, and together with Life Sciences, the “Funds”) which may be deemed to be indirectly beneficially owned by the Reporting Persons, as well as Common Stock that may be acquired upon the exercise of pre-funded warrants with no expiration date with an exercise price of $0.0001 per share of Common Stock (“Pre-Funded Warrants”), subject to the limitations on exercise described below.

     

    The information set forth below is based on 50,624,606 shares of Common Stock outstanding as of November 8, 2023, as reported in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on December 1, 2023. Such percentage figures are calculated in accordance with Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

     

     

    Holder   Number of Shares of Common
    Stock we own or have the right
    to acquire within 60 days
        Percent of Class
    Outstanding
     
    667, L.P.     196,793       0.39 %
    Baker Brothers Life Sciences, L.P.     2,330,879       4.60 %
    Total     2,527,672       4.99 %

     

    The Pre-Funded Warrants are only exercisable to the extent that after giving effect or immediately prior to such exercise the holders thereof, their affiliates and any person who are members of a Section 13(d) group with the holders or one of their affiliates would beneficially own in the aggregate, for purposes of Rule 13d-3 under the Exchange Act, no more than 4.99% of the outstanding Common Stock (the “Maximum Percentage”). By written notice to the Issuer, the Funds may from time to time increase or decrease the Maximum Percentage applicable to that Fund to any other percentage not in excess of 19.99%. Any such increase will not be effective until the 61st day after such notice is delivered to the Issuer. As a result of this restriction, the number of shares of Common Stock that may be issued upon exercise of the Pre-Funded Warrants by the above holders may change depending upon changes in the outstanding Common Stock.

     

    The Adviser GP, Felix J. Baker and Julian C. Baker as managing members of the Adviser GP, and the Adviser may be deemed to be beneficial owners of securities of the Issuer directly held by the Funds.

     

    The Adviser GP is the sole general partner of the Adviser. Pursuant to the management agreements, as amended, among the Adviser, Life Sciences and 667 and their respective general partners, the Funds’ respective general partners relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds, and thus the Adviser has complete and unlimited discretion and authority with respect to the Funds’ investments and voting power over investments.

     

    Item 5 Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x.

     

    Item 6 Ownership of More than Five Percent on Behalf of Another Person:

     

    N/A

     

     

    Item 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    The information in Item 4 is incorporated herein by reference.

     

    Item 8 Identification and Classification of Members of the Group:

     

    N/A

     

    Item 9 Notice of Dissolution of Group:

     

    N/A

     

    Item 10 Certification:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 14, 2024

     

     

    BAKER BROS. ADVISORS LP

     

    By: Baker Bros. Advisors (GP) LLC, its general partner

     

      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

      BAKER BROS. ADVISORS (GP) LLC
         
      By: /s/ Scott L. Lessing
        Name: Scott L. Lessing
    Title: President

     

        /s/ Julian C. Baker
        Julian C. Baker
       
        /s/ Felix J. Baker
        Felix J. Baker

     

     

    Get the next $TSVT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TSVT

    DatePrice TargetRatingAnalyst
    6/6/2024$5.00 → $2.00Neutral → Sell
    Goldman
    1/31/2024Outperform → Market Perform
    TD Cowen
    1/31/2024$5.00 → $18.00Market Perform → Outperform
    Leerink Partners
    10/30/2023$6.00Outperform → Market Perform
    Leerink Partners
    10/12/2023$13.00Buy
    Citigroup
    9/13/2023$5.00Buy → Neutral
    Goldman
    9/12/2023Buy → Neutral
    Guggenheim
    7/28/2023$25.00 → $13.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $TSVT
    Leadership Updates

    Live Leadership Updates

    See more
    • 2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors

      2seventy bio, Inc. (NASDAQ:TSVT), announced today that Eli Casdin, Chief Investment Officer, and Founder of Casdin Capital, and Charles Newton, Chief Financial Officer, Lyell Immunopharma, have been appointed as new independent members of the Company's Board of Directors (the "Board"), effective immediately. Casdin Capital owns approximately 2.3% of 2seventy bio's outstanding shares as of 03/20/24. "We are pleased to welcome Eli and Charlie to the 2seventy Board," said Dan Lynch, chair of the Board of Directors. "Eli is a highly regarded, leading life sciences and healthcare investor and has a deep understanding of and history with the Company. Charlie has a track record of helping compan

      3/20/24 5:04:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Engine Capital Sends Letter to 2seventy's Board of Directors Outlining Steps to Maximize Shareholder Value

      Believes 2seventy Could Be Conservatively Worth ~$9 Per Share if the Company Exclusively Focuses on Its Most-Valuable Asset Abecma, Reduces Corporate Overhead and Makes Improvements to the Composition of the Management Team and Board Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.'s (NASDAQ:TSVT) ("2seventy" or the "Company") outstanding shares, today announced that it sent the below letter the Company's Board of Directors (the "Board"). *** December 6, 2023 2seventy bio, Inc. 60 Binney Street Cambridge, MA 02142 Attention: Board of Directors Dear Members of the Board: Engine Capital LP (together with its affiliates, "Engine" or "we"), is a meaningful shareh

      12/6/23 8:00:00 AM ET
      $BLUE
      $TSVT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Deep Genomics Announces the Appointment of Brian O'Callaghan as CEO

      O'Callaghan, a well-regarded life-science business leader with global experience and a significant track record of success, joins as part of plan to evolve Deep Genomics as a forward-integrated biopharmaceutical company Founder and current CEO Brendan Frey, Ph.D., F.R.S.C. to assume new role of chief innovation officer, remain a member of the board and bolster plans for further technology development and innovation, leveraging artificial intelligence (AI) to decode RNA biology for novel drug development Lead independent director Chip Baird appointed as chair of the board Deep Genomics, a leading AI drug development company focused on decoding biology to program life-changing medicines

      9/15/23 7:00:00 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    SEC Filings

    See more
    • SEC Form 10-Q filed by 2seventy bio Inc.

      10-Q - 2seventy bio, Inc. (0001860782) (Filer)

      5/7/25 4:16:20 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - 2seventy bio, Inc. (0001860782) (Filer)

      5/7/25 4:12:38 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by 2seventy bio Inc.

      SC TO-T/A - 2seventy bio, Inc. (0001860782) (Subject)

      5/6/25 7:57:30 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

      Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas

      5/7/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

      Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million U.S. sales in 2024 79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure a

      3/25/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb

      $5.00 per share, all-cash transaction Expected to close in the second quarter of 2025, subject to customary closing conditions 2seventy bio, Inc. (NASDAQ:TSVT), today announced a definitive merger agreement under which Bristol Myers Squibb (NYSE:BMY) ("BMS") will acquire all of the outstanding shares of 2seventy bio at a price of $5.00 per share in an all-cash transaction for a total equity value of approximately $286 million, or $102 million net of estimated cash. The deal represents an 88% premium to the closing price of $2.66 on March 7, 2025. "A year ago, 2seventy decided to exclusively focus on unlocking the value of Abecma, with the goal of delivering more time for people living wi

      3/10/25 10:17:00 PM ET
      $BMY
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $TSVT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TSVT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by 2seventy bio Inc.

      SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)

      11/6/24 4:06:39 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 2seventy bio Inc. (Amendment)

      SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)

      2/14/24 4:58:16 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by 2seventy bio Inc. (Amendment)

      SC 13G/A - 2seventy bio, Inc. (0001860782) (Subject)

      2/14/24 4:21:54 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio downgraded by Goldman with a new price target

      Goldman downgraded 2seventy bio from Neutral to Sell and set a new price target of $2.00 from $5.00 previously

      6/6/24 7:21:43 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio downgraded by TD Cowen

      TD Cowen downgraded 2seventy bio from Outperform to Market Perform

      1/31/24 9:14:22 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded 2seventy bio from Market Perform to Outperform and set a new price target of $18.00 from $5.00 previously

      1/31/24 7:24:00 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Snow Jessica sold $11,364 worth of shares (2,298 units at $4.95), decreasing direct ownership by 0.90% to 254,193 units (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/19/25 4:49:01 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Baird William D Iii sold $25,180 worth of shares (5,092 units at $4.95), decreasing direct ownership by 0.45% to 1,121,034 units (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/19/25 4:48:27 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Eatwell Victoria sold $12,817 worth of shares (2,592 units at $4.95), decreasing direct ownership by 0.58% to 444,387 units (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/19/25 4:48:17 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Financials

    Live finance-specific insights

    See more
    • 2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb

      Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas

      5/7/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Reports Fourth Quarter and Full Year 2024 Financial Results

      Entered into definitive merger agreement to be acquired by Bristol Myers Squibb at a price of $5.00 per share in an all-cash transaction; expected to close in the second quarter of 2025 Abecma generated $242 million U.S. sales in 2024 79% reduction in year-over-year net cash spend reflects continued streamlining of cost structure Ended 2024 with approximately $184 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. "2024 was a pivotal year for 2seventy as we made significant changes to our business to streamline cost structure a

      3/25/25 4:05:00 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress

      Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in anticipated cost savings over the next several years 24% reduction in operating expenses versus the second quarter reflects continued progress on streamlining 2seventy's cost structure; third quarter net loss of approximately $10 million Ended quarter with approximately $192 million in cash, cash equivalents, and marketable securities; expected cash runway beyond 2027 Conference call today at 8:00 AM ET 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for

      11/12/24 7:00:00 AM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TSVT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Casdin Capital, Llc bought $203,992 worth of shares (40,000 units at $5.10) (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/28/24 8:29:09 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Casdin Capital, Llc bought $3,899,050 worth of shares (777,377 units at $5.02) (SEC Form 4)

      4 - 2seventy bio, Inc. (0001860782) (Issuer)

      3/25/24 9:44:59 PM ET
      $TSVT
      Biotechnology: Pharmaceutical Preparations
      Health Care